ArticleFrontiers in endocrinology2023
How patients experience thyroid eye disease.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey.Ophthalmology and therapy · 2026Article
- Quality of life and psychosocial well-being in thyroid eye disease in Japan: pre-teprotumumab national survey.Journal of the Endocrine Society · 2026Article
- Clinically accessible eye-tracking in thyroid-associated ophthalmopathy: exploratory classification modeling and gaze allocation to disease-related periocular images.BMC ophthalmology · 2026Article
- Approach to the patient: therapeutic mitigation of lacrimal manifestations in thyroid eye disease.The Journal of clinical endocrinology and metabolism · 2026Review
- Review
- What has changed in thyroid eye disease in the last five years (2020-2025).European thyroid journal · 2026Review
- Development and external validation of a nomogram for identifying patients with thyroid eye disease who screen positive for depressive symptoms: a two-center study.Frontiers in endocrinology · 2026Observational
- Risk-centered benchmarking of large language models for AI-enabled counseling in chronic autoimmune thyroid eye disease.Frontiers in cell and developmental biology · 2026Article
- Diagnostic methods for managing dry eyes.World journal of methodology · 2025Article
- Immunomodulatory Effects ofNutrients · 2025Article
- Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved?Journal of endocrinological investigation · 2025Review
- The Use of Biologics for Thyroid Eye Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Deep learning system for the auxiliary diagnosis of thyroid eye disease: evaluation of ocular inflammation, eyelid retraction, and eye movement disorder.Frontiers in cell and developmental biology · 2025Article
- The burden of illness in thyroid eye disease: current state of the evidence.Frontiers in ophthalmology · 2025Review
- A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2024Review
- Thyroid Eye Disease: Advancements in Orbital and Ocular Pathology Management.Journal of personalized medicine · 2024Review
- TikTok as a potential patient educational tool for thyroid-associated ophthalmopathy: A cross-sectional study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the impact of thyroid eye disease (TED) on patients in various stages of the disease. Background: TED is a debilitating and potentially sight-threatening inflammatory autoimmune disease that is frequently misdiagnosed. Challenging quality-of-life (QoL) issues can persist long after the active phase of disease has subsided. Methods: A 62-question survey was designed as a hypothesis-generating instrument to identify key issues confronting patients ≥18 years old with physician-diagnosed TED. Questions focused primarily on physical and emotional status, and QoL experiences in the 2 months prior to the survey. Data for individual questions are presented as summary statistics. Correlations between questions were determined using χ Results: The 443 respondents were 18 to >80 years old; >90% female, and >80% from the United States. Time since TED diagnosis ranged from <1 year to >10 years. Participants provided >500 free-form responses describing experiences of living with TED. Physical signs/symptoms were experienced by 307/443 (69%) patients. Of those responding to the QoL questions (N = 394), 53 (13%) reported symptoms improving, 73 (19%) reported symptoms worsening, and 255 (65%) reported no change in the 2 months prior to the survey. The most bothersome signs/symptoms were dry/gritty eyes, light sensitivity, bulging eyes, and pressure or pain behind the eyes. Respondents <60 years were significantly (p < 0.0001) more likely to report symptomatic TED than older patients. Of 394 respondents, 179 (45%) reported feeling depressed and/or anxious, 174 (44%) reported concern about their appearance, and 73 (19%) avoided public situations; 192 (49%) reported declines in confidence or feelings of general well-being, and 78 (20%) reported an inability to achieve goals. Activities limited by TED included reading, driving, and socializing. The proportion of respondents experiencing these negative QoL measures was higher when patients reported experiencing >5 symptoms, had been diagnosed within the last 5 years, or were <60 years of age. Conclusions: Physical manifestations of TED impact QoL for patients through all phases of the disease. It is essential that physicians and healthcare professionals become more familiar with patient experiences such as those described here to better help patients manage their disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.